Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $9.60 Consensus PT from Brokerages

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has been given a consensus recommendation of “Hold” by the six research firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $9.60.

A number of brokerages have recently issued reports on VRCA. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, November 5th. Royal Bank of Canada downgraded shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $11.00 to $2.00 in a report on Tuesday, November 5th. HC Wainwright lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 6th. TD Cowen dropped their target price on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, October 21st. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several institutional investors have recently bought and sold shares of VRCA. Sanctuary Advisors LLC purchased a new stake in Verrica Pharmaceuticals in the 3rd quarter worth $87,000. Barclays PLC increased its holdings in shares of Verrica Pharmaceuticals by 404.6% in the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after purchasing an additional 25,130 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Verrica Pharmaceuticals in the third quarter worth about $335,000. Jane Street Group LLC boosted its stake in Verrica Pharmaceuticals by 106.5% during the third quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after buying an additional 36,028 shares during the last quarter. Finally, State Street Corp grew its holdings in Verrica Pharmaceuticals by 13.5% during the 3rd quarter. State Street Corp now owns 512,821 shares of the company’s stock valued at $744,000 after buying an additional 61,041 shares in the last quarter. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Stock Down 8.2 %

NASDAQ:VRCA opened at $0.80 on Tuesday. The company has a debt-to-equity ratio of 29.58, a current ratio of 1.34 and a quick ratio of 1.22. The firm’s 50-day moving average price is $1.19 and its 200-day moving average price is $3.92. The company has a market capitalization of $36.60 million, a PE ratio of -0.44 and a beta of 1.40. Verrica Pharmaceuticals has a 1-year low of $0.70 and a 1-year high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of ($1.78) million for the quarter, compared to analysts’ expectations of $7.53 million. On average, equities analysts predict that Verrica Pharmaceuticals will post -1.42 EPS for the current fiscal year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.